Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004339 · ClinicalTrials.gov registry record · Phase 3
Study of Tetrathiomolybdate in Patients With Wilson Disease
A Phase 3 study, sponsored by National Center for Research Resources (NCRR).
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT00004339 is a Phase 3 study that has completed, run by National Center for Research Resources (NCRR). The registered enrollment target is 90 participants.
The verdict
NCT00004339, a Phase 3 study, has completed, sponsored by National Center for Research Resources (NCRR).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
OBJECTIVES: Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically.
Interventions
- DRUG tetrathiomolybdate
- DRUG trientine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 1994-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004339
The ClinicalTrials.gov registry entry for NCT00004339 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Research Resources (NCRR), which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tetrathiomolybdate is the first listed.
NCT00004339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004339 about?
NCT00004339 is a clinical study titled "Study of Tetrathiomolybdate in Patients With Wilson Disease". OBJECTIVES: Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically.
What is the current status of trial NCT00004339?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 1994-01.
What interventions are being tested in trial NCT00004339?
The interventions under investigation include: tetrathiomolybdate (DRUG), trientine (DRUG).
Who is sponsoring clinical trial NCT00004339?
This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.